PRESCRIPTION DRUG PRICING

America's Prescription Problem: Drug Affordability Remains Out of Reach

70%

of drug manufacturers' profit **comes from the U.S. market.**[1]



Americans bankroll pharmaceutical companies

$776B

or a 73% projected increase in **annual Medicare drug spend** by 2033.[2]



Unsustainable spending

$2.5M

average spend on **single gene therapy,** with **nearly 20 approved annually.**[3]



Broken financing systems

88%

of drug costs are spent on **brand-name drugs.**[4]



Manufacturers block generic and biosimilar access

$324B

Medicare dollars spent on advertised brand-name drugs from 2016-2018.[5]



Inappropriate direct-to-consumer advertising

80%

of the market is controlled by **three pharmacy benefit managers** (PBMs).[6]



Monopolized drug supply chain

Every patient deserves access to the *right* medicine, at an *affordable* price, when they *need* it.

The ACHP Fix List: Reforms for a *Fair* and *Effective* Drug Marketplace

1 Lower Prices

Secure lower drug prices that are transparent and reflect taxpayer contributions.

2 Sustainable Spending

Condition federal coverage on evidence of cost-effectiveness and proven clinical benefit.

3 Innovative Financing

Establish a national risk pool for high-cost therapies for rare diseases such as Hemophilia B and Duchenne Muscular Dystrophy.

4 Cut Patent Thickets/ Allow Interchangeability

Reform patents to increase access to generics and remove burdensome interchangeability requirements to promote biosimilar adoption.

5 Restrict Advertising

End tax breaks, require price disclosures and increase FDA enforcement for direct-to-consumer drug advertisements.

6 Enforce Supply Chain Transparency

Eliminate patient steering and hidden price hikes by pharmaceutical manufacturers and PBMs.

Scan to learn more about ACHP's drug pricing policy positions.

For more information please contact **ACHPadvocacy@achp.org**.